个人中心 - 老虎社区

AK1208

IP属地：未知

帖子 · 11帖子 · 11
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- AK1208AK1208
  ·2021-06-24
  Interesting
  非常抱歉，此主贴已删除
  1,275 1
  1
  分享
  举报
- AK1208AK1208
  ·2021-06-24
  Cool
  非常抱歉，此主贴已删除
  1,052 1
  5
  分享
  举报
- AK1208AK1208
  ·2021-06-23
  Cool
  非常抱歉，此主贴已删除
  1,144 评论
  1
  分享
  举报
- AK1208AK1208
  ·2021-06-23
  Wow
  非常抱歉，此主贴已删除
  1,135 评论
  点赞
  分享
  举报
- AK1208AK1208
  ·2021-06-22
  Wow
  非常抱歉，此主贴已删除
  871 1
  3
  分享
  举报
- AK1208AK1208
  ·2021-06-22
  Cool
  非常抱歉，此主贴已删除
  1,120 评论
  1
  分享
  举报
- AK1208AK1208
  ·2021-06-21
  Wow
  非常抱歉，此主贴已删除
  1,155 1
  1
  分享
  举报
- AK1208AK1208
  ·2021-06-20
  Noted
  非常抱歉，此主贴已删除
  1,074 评论
  1
  分享
  举报
- AK1208AK1208
  ·2021-06-19
  Wow
  非常抱歉，此主贴已删除
  1,343 评论
  2
  分享
  举报
- AK1208AK1208
  ·2021-06-18
  Awesome
  Clearside Jumps; Wedbush Triples Target After Eye-Drug Trial Progress<blockquote>克利尔赛德跳跃；眼部药物试验取得进展后，韦德布什将目标提高了两倍</blockquote>
  Shares of Clearside Biomedical(CLSD) jumped on Thursday after analysts at Wedbush tripled their pri
  Clearside Jumps; Wedbush Triples Target After Eye-Drug Trial Progress<blockquote>克利尔赛德跳跃；眼部药物试验取得进展后，韦德布什将目标提高了两倍</blockquote>
  1,520 评论
  点赞
  分享
  举报

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3582542713091138","uuid":"3582542713091138","gmtCreate":1619491143389,"gmtModify":1619491143389,"name":"AK1208","pinyin":"ak1208","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":4,"tweetSize":11,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.10.25","exceedPercentage":"80.50%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.02.22","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":12,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":126143058,"gmtCreate":1624548770474,"gmtModify":1634004491816,"author":{"id":"3582542713091138","authorId":"3582542713091138","name":"AK1208","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582542713091138","idStr":"3582542713091138"},"themes":[],"htmlText":"Interesting&nbsp;","listText":"Interesting&nbsp;","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/126143058","repostId":"1120836318","repostType":4,"isVote":1,"tweetType":1,"viewCount":1275,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":126140402,"gmtCreate":1624548717406,"gmtModify":1634004492511,"author":{"id":"3582542713091138","authorId":"3582542713091138","name":"AK1208","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582542713091138","idStr":"3582542713091138"},"themes":[],"htmlText":"Cool&nbsp;","listText":"Cool&nbsp;","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/126140402","repostId":"1162964404","repostType":4,"isVote":1,"tweetType":1,"viewCount":1052,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":129499299,"gmtCreate":1624379715411,"gmtModify":1634006949785,"author":{"id":"3582542713091138","authorId":"3582542713091138","name":"AK1208","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582542713091138","idStr":"3582542713091138"},"themes":[],"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/129499299","repostId":"1118580429","repostType":4,"isVote":1,"tweetType":1,"viewCount":1144,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":129400702,"gmtCreate":1624379359706,"gmtModify":1634006956522,"author":{"id":"3582542713091138","authorId":"3582542713091138","name":"AK1208","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582542713091138","idStr":"3582542713091138"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/129400702","repostId":"1118580429","repostType":4,"isVote":1,"tweetType":1,"viewCount":1135,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":120926014,"gmtCreate":1624292738838,"gmtModify":1634008229069,"author":{"id":"3582542713091138","authorId":"3582542713091138","name":"AK1208","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582542713091138","idStr":"3582542713091138"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/120926014","repostId":"2145084835","repostType":4,"isVote":1,"tweetType":1,"viewCount":871,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":120929331,"gmtCreate":1624292558223,"gmtModify":1634008231903,"author":{"id":"3582542713091138","authorId":"3582542713091138","name":"AK1208","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582542713091138","idStr":"3582542713091138"},"themes":[],"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/120929331","repostId":"1186997776","repostType":4,"isVote":1,"tweetType":1,"viewCount":1120,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":164220477,"gmtCreate":1624209701799,"gmtModify":1634009449434,"author":{"id":"3582542713091138","authorId":"3582542713091138","name":"AK1208","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582542713091138","idStr":"3582542713091138"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/164220477","repostId":"2144218770","repostType":4,"isVote":1,"tweetType":1,"viewCount":1155,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":165543938,"gmtCreate":1624153212724,"gmtModify":1634010252883,"author":{"id":"3582542713091138","authorId":"3582542713091138","name":"AK1208","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582542713091138","idStr":"3582542713091138"},"themes":[],"htmlText":"Noted&nbsp;","listText":"Noted&nbsp;","text":"Noted","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/165543938","repostId":"1183124175","repostType":4,"isVote":1,"tweetType":1,"viewCount":1074,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":162557987,"gmtCreate":1624069075849,"gmtModify":1634011142852,"author":{"id":"3582542713091138","authorId":"3582542713091138","name":"AK1208","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582542713091138","idStr":"3582542713091138"},"themes":[],"htmlText":"Wow&nbsp;","listText":"Wow&nbsp;","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/162557987","repostId":"2144771068","repostType":4,"isVote":1,"tweetType":1,"viewCount":1343,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":168986782,"gmtCreate":1623946848746,"gmtModify":1634025396950,"author":{"id":"3582542713091138","authorId":"3582542713091138","name":"AK1208","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582542713091138","idStr":"3582542713091138"},"themes":[],"htmlText":"Awesome","listText":"Awesome","text":"Awesome","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/168986782","repostId":"1179547045","repostType":4,"repost":{"id":"1179547045","kind":"news","pubTimestamp":1623941450,"share":"https://www.laohu8.com/m/news/1179547045?lang=zh_CN&edition=full","pubTime":"2021-06-17 22:50","market":"us","language":"en","title":"Clearside Jumps; Wedbush Triples Target After Eye-Drug Trial Progress<blockquote>克利尔赛德跳跃；眼部药物试验取得进展后，韦德布什将目标提高了两倍</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1179547045","media":"thestreet","summary":"Shares of Clearside Biomedical(CLSD)  jumped on Thursday after analysts at Wedbush tripled their pri","content":"<p>Shares of Clearside Biomedical(<b>CLSD</b>) &nbsp;jumped on Thursday after analysts at Wedbush tripled their price target for the company following positive data from the early stage eye treatment study.</p><p><blockquote>Clearside Biomedical股票(<b>CLSD</b>在早期眼科治疗研究的积极数据公布后，韦德布什分析师将该公司的目标价提高了两倍，周四股价上涨。</blockquote></p><p> Wedbush analyst Liana Moussatos rates the stock outperform and tripled her price target to $18 a share.</p><p><blockquote>Wedbush分析师Liana Moussatos将该股评级为跑赢大盘，并将目标价提高了两倍至每股18美元。</blockquote></p><p> \"We find these initial results encouraging by first establishing a clear foundation of safety,\" Moussatos said.</p><p><blockquote>穆萨托斯说：“首先建立了明确的安全基础，我们发现这些初步结果令人鼓舞。”</blockquote></p><p> Shares of Clearside Biomedical at last check jumped 36% to $5.53. The shares on Thursday have traded at a 52-week high $5.66, up 39%. And they've bounced off a 52-week low $1.25, touched at the end of October.</p><p><blockquote>上次检查时，Clearside Biomedical的股价上涨36%，至5.53美元。周四，该股交易价格为52周高点5.66美元，上涨39%。它们已从10月底触及的52周低点1.25美元反弹。</blockquote></p><p> Clearside shares have been volatile, falling as low as $2.24 per share in late March. But since the calendar flipped to June, the stock as jumped more than 50%, including Thursday's jump.</p><p><blockquote>Clearside股价波动较大，3月底跌至每股2.24美元。但自从日历翻到6月以来，该股上涨了50%以上，其中包括周四的上涨。</blockquote></p><p> Earlier this week the company&nbsp;reported progress in a clinical trial of CLS-AX, a drug for pretreated wet age-related macular degeneration.</p><p><blockquote>本周早些时候，该公司报告了CLS-AX的临床试验进展，CLS-AX是一种用于预处理湿性年龄相关性黄斑变性的药物。</blockquote></p><p> Clearside said the initial lowest planned dose of 0.03 mg CLS-AX was well tolerated with no serious adverse events and no drug-related treatment-emergent adverse events observed throughout the study.</p><p><blockquote>Clearside表示，0.03 mg CLS-AX的初始最低计划剂量耐受性良好，在整个研究过程中没有观察到严重的不良事件，也没有观察到与药物相关的治疗中出现的不良事件。</blockquote></p><p> The company said the improvements were reflected in the BCVA score, or best corrected visual acuity, with five of six patients each gaining four or more letters.</p><p><blockquote>该公司表示，这些改善反映在BCVA评分（即最佳矫正视力）中，六分之五的患者每人获得了四个或更多字母。</blockquote></p><p> Earlier this week the results prompted an analyst to call the treatment \"a game changer.\" Roth Capital analyst Zegbeh Jallah reiterated a buy rating and $9 price target on Clearside after the company reported data from the study.</p><p><blockquote>本周早些时候，结果促使一位分析师将这种治疗方法看涨期权为“游戏规则改变者”。在Clearside报告研究数据后，Roth Capital分析师Zegbeh Jallah重申了该公司的买入评级和9美元的目标价。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clearside Jumps; Wedbush Triples Target After Eye-Drug Trial Progress<blockquote>克利尔赛德跳跃；眼部药物试验取得进展后，韦德布什将目标提高了两倍</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClearside Jumps; Wedbush Triples Target After Eye-Drug Trial Progress<blockquote>克利尔赛德跳跃；眼部药物试验取得进展后，韦德布什将目标提高了两倍</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">thestreet</strong><span class=\"h-time small\">2021-06-17 22:50</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Shares of Clearside Biomedical(<b>CLSD</b>) &nbsp;jumped on Thursday after analysts at Wedbush tripled their price target for the company following positive data from the early stage eye treatment study.</p><p><blockquote>Clearside Biomedical股票(<b>CLSD</b>在早期眼科治疗研究的积极数据公布后，韦德布什分析师将该公司的目标价提高了两倍，周四股价上涨。</blockquote></p><p> Wedbush analyst Liana Moussatos rates the stock outperform and tripled her price target to $18 a share.</p><p><blockquote>Wedbush分析师Liana Moussatos将该股评级为跑赢大盘，并将目标价提高了两倍至每股18美元。</blockquote></p><p> \"We find these initial results encouraging by first establishing a clear foundation of safety,\" Moussatos said.</p><p><blockquote>穆萨托斯说：“首先建立了明确的安全基础，我们发现这些初步结果令人鼓舞。”</blockquote></p><p> Shares of Clearside Biomedical at last check jumped 36% to $5.53. The shares on Thursday have traded at a 52-week high $5.66, up 39%. And they've bounced off a 52-week low $1.25, touched at the end of October.</p><p><blockquote>上次检查时，Clearside Biomedical的股价上涨36%，至5.53美元。周四，该股交易价格为52周高点5.66美元，上涨39%。它们已从10月底触及的52周低点1.25美元反弹。</blockquote></p><p> Clearside shares have been volatile, falling as low as $2.24 per share in late March. But since the calendar flipped to June, the stock as jumped more than 50%, including Thursday's jump.</p><p><blockquote>Clearside股价波动较大，3月底跌至每股2.24美元。但自从日历翻到6月以来，该股上涨了50%以上，其中包括周四的上涨。</blockquote></p><p> Earlier this week the company&nbsp;reported progress in a clinical trial of CLS-AX, a drug for pretreated wet age-related macular degeneration.</p><p><blockquote>本周早些时候，该公司报告了CLS-AX的临床试验进展，CLS-AX是一种用于预处理湿性年龄相关性黄斑变性的药物。</blockquote></p><p> Clearside said the initial lowest planned dose of 0.03 mg CLS-AX was well tolerated with no serious adverse events and no drug-related treatment-emergent adverse events observed throughout the study.</p><p><blockquote>Clearside表示，0.03 mg CLS-AX的初始最低计划剂量耐受性良好，在整个研究过程中没有观察到严重的不良事件，也没有观察到与药物相关的治疗中出现的不良事件。</blockquote></p><p> The company said the improvements were reflected in the BCVA score, or best corrected visual acuity, with five of six patients each gaining four or more letters.</p><p><blockquote>该公司表示，这些改善反映在BCVA评分（即最佳矫正视力）中，六分之五的患者每人获得了四个或更多字母。</blockquote></p><p> Earlier this week the results prompted an analyst to call the treatment \"a game changer.\" Roth Capital analyst Zegbeh Jallah reiterated a buy rating and $9 price target on Clearside after the company reported data from the study.</p><p><blockquote>本周早些时候，结果促使一位分析师将这种治疗方法看涨期权为“游戏规则改变者”。在Clearside报告研究数据后，Roth Capital分析师Zegbeh Jallah重申了该公司的买入评级和9美元的目标价。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.thestreet.com/investing/clearside-biomedical-stock-jumps-on-wedbush-upgrade\">thestreet</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CLSD":"Clearside Biomedical Inc."},"source_url":"https://www.thestreet.com/investing/clearside-biomedical-stock-jumps-on-wedbush-upgrade","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1179547045","content_text":"Shares of Clearside Biomedical(CLSD)  jumped on Thursday after analysts at Wedbush tripled their price target for the company following positive data from the early stage eye treatment study.\nWedbush analyst Liana Moussatos rates the stock outperform and tripled her price target to $18 a share.\n\"We find these initial results encouraging by first establishing a clear foundation of safety,\" Moussatos said.\nShares of Clearside Biomedical at last check jumped 36% to $5.53. The shares on Thursday have traded at a 52-week high $5.66, up 39%. And they've bounced off a 52-week low $1.25, touched at the end of October.\nClearside shares have been volatile, falling as low as $2.24 per share in late March. But since the calendar flipped to June, the stock as jumped more than 50%, including Thursday's jump.\nEarlier this week the company reported progress in a clinical trial of CLS-AX, a drug for pretreated wet age-related macular degeneration.\nClearside said the initial lowest planned dose of 0.03 mg CLS-AX was well tolerated with no serious adverse events and no drug-related treatment-emergent adverse events observed throughout the study.\nThe company said the improvements were reflected in the BCVA score, or best corrected visual acuity, with five of six patients each gaining four or more letters.\nEarlier this week the results prompted an analyst to call the treatment \"a game changer.\" Roth Capital analyst Zegbeh Jallah reiterated a buy rating and $9 price target on Clearside after the company reported data from the study.","news_type":1,"symbols_score_info":{"CLSD":0.9}},"isVote":1,"tweetType":1,"viewCount":1520,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":false}